GenEdit Appoints Dr. J. Rodrigo Mora as Chief Scientific Officer to Expand Its NanoGalaxy® Genetic Medicine Platform into Immunology

calendar_today November 13, 2024 person genedit_admin domain breezebio

SOUTH SAN FRANCISCO, Calif., November 13, 2024 – GenEdit, Inc., a developer of genetic medicines that leverage its NanoGalaxy platform for tissue-selective delivery, today announced the appointment of J. Rodrigo Mora, M.D., Ph.D., as Chief Scientific Officer (CSO). Dr.

open_in_new Read original post

Discovery

Learnings

Guidance

Toolbox

Alignment

API Evangelist LLC

GenEdit Appoints Dr. J. Rodrigo Mora as Chief Scientific Officer to Expand Its NanoGalaxy® Genetic Medicine Platform into Immunology